Published in Vaccine Weekly, December 14th, 2005
According to a study from the Netherlands, "Potent liposomal PorA formulations containing various lipopolysaccharide (LPS) derivatives were developed. The following adjuvants were compared: the commonly used aluminum phosphate (AlPO4 ), and three LPS like adjuvants: monophosphoryl lipid A (MPL), lipopolysaccharide (gaff LPS), and the less toxic LPS mutant lpxL1. The immunogenicity in mice was evaluated and compared with that against an outer membrane vesicle (OMV) vaccine. The IgG isotype distribution and bactericidal activity were determined."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly